Interestingly, our study found that there was certain expression of Galectin-9 in the terminally exhausted CD8+TILs in DLBCL, which might aggravate the exhaustion of CD8+TILs through TIM3/Galectin-9 pathway and further weaken the anti-tumor function of CD8+TILs. The gene discussed is CD8A; the disease is neoplasm.